Message Font: Serif | Sans-Serif
No. of Recommendations: 1
Boston Scientific's new stent may get priority review

Boston Scientific Corp. (NYSE:BSX - News) said on Thursday its experimental device for preventing re-clogging of arteries would likely be reviewed more quickly than normal by U.S. regulators.


Boston Scientific said the U.S. Food and Drug Administration (News - Websites) will review the company's Taxus stent before it reviews pending applications on other drugs and devices.


Johnson & Johnson (NYSE:JNJ - News) is already marketing it drug-coated stent, called Cypher, in Europe and is awaiting U.S. approval.

Boston Scientific has said it expects sales to jump to $5.4 billion in 2004 from a projected $3.4 billion in 2003 as its drug-coated stent becomes widely used. Taxus is already approved in Europe.
Print the post  


What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.